CBAY News and Press, CymaBay Therapeutics Inc. From 05/09/23

2023-05-09 08:19:46 ET Summary I present additional information about my methodology for finding the best stocks. Some of the technical tools I use to make final decisions to buy or sell. The leadership of certain stocks and sectors changes occasionally, and we can take this i...

2023-05-09 08:13:16 ET Clinical-stage biopharmaceutical company, CymaBay Therapeutics ( NASDAQ: CBAY ) announced that seasoned biopharma executive Harish Shantharam, CFA has joined the company as CFO. Mr. Shantharam brings nearly 20 years of biotech experien...

Proven Leader in Building Financial Organizations to Prepare Company for Successful Commercialization Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions NEWARK, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a...

2023-05-04 03:08:32 ET Summary My journey on the road to finding the best portfolio. My early attempts to find the best stocks in which to invest. My success in finding the best methods. I feel it is about time to publish my latest stock recommendations as I have, I ...

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved -5.82% on the day to $10.2. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...

2023-04-28 15:00:41 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the ENHANCE phase 3 gl...

NEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwrig...

2023-04-05 08:47:36 ET William Blair has initiated CymaBay Therapeutics with a buy rating on the promise of its phase 3 candidate seladelpar  for the autoimmune liver disease, primary biliary cholangitis ( PBC ). The firm does not have a target price. Analys...

2023-03-23 17:01:12 ET Gainers: Pyxis Oncology ( PYXS ) +15% . CRISPR Therapeutics ( CRSP ) +11% . ADMA Biologics ( ADMA ) +6% . Harrow Health ( HROW ) +4% . Solid Power ( SLDP ) +5% . Losers: Scholastic ( SCHL ) -1...